Skip to content
TriangleGet started
← Study library

NCT00217737 · CITED IN SOURCE DOCUMENTS

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2026-08-25

This randomized phase III trial studies oxaliplatin, leucovorin, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Disease-free Survival Rate at 5 Years

→

outcome · POSTED

Overall Survival Rate at 5 Years

→

outcome · POSTED

The Impact of Tumor Biological Characteristics on Overall Survival

→

outcome · NOT POSTED

The Association Between Oxaliplatin Exposure, Allelic Variants in Candidate Genes, and Neurotoxicity

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * STEP 1: INITIAL REGISTRATION * The distal extent of the tumor must be \>= 12 cm from the anal verge on endoscopy; if this distance was not confirmed on endoscopy pre-operatively, then the distal extent of the tumor must be \>= 12 cm from the anal verge as determined by surgical examination; colonoscopy should be performed postoperatively for those unable to have a preoperative colonoscopy to guarantee there are no synchronous lesions * Patients must have paraffin-embedded tumor specimen available for evaluation of microsatellite instability and loss of heterozygosity at 18q, to determine high risk versus low risk * High-risk patients will be randomized to treatment Arms A or B * Low-risk patients will be registered to Arm C for observation * NOTE: Every effort should be made to submit blocks (tumor and normal mucosa) to the Principal Coordinates Analysis (PCO) immediately; blocks CANNOT be accepted after day 50 (post surgery) in order to allow for molecular assessment * Specific laboratory requirements for Step 2 must be obtained within 2 weeks prior to Step 2 randomization * Patients must not have synchronous tumors * Patients must not have appendiceal tumors * Patients must not have a history of inflammatory bowel disease (IBD) * Patients with hereditary non-polyposis colorectal cancer (HNPCC) are eligible * Patients must have no history of isolated, distant, or non-contiguous intra-abdominal metastases, even if restricted * Patients must have histologically confirmed adenocarcinoma of the colon that meets the criteria below: * Stage II adenocarcinoma (pT3/pT4a/pT4b pN0 M0 according to the definitions of the American Joint Committee on Cancer, 7th Edition, 2010): the tumor invades through the muscularis propria into pericolic tissues (pT3), penetrates to the surface of the visceral peritoneum (pT4a), or directly invades other organs or structures (pT4b); patients with mesenteric tumor deposits or satellites without identifiable residual lymph node in the absence of lymph node involvement are now designated pN1c, rather than pT3; patients with such tumor deposits are not eligible for E5202; patients must have had a complete resection (R0 resection) * Patients must have \>= 8 lymph nodes evaluated and reported * Patients must not have presented with clinical complete obstruction or perforation of the bowel * Patients must not have had any systemic or radiation therapy initiated for this malignancy * Patients must not have a previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions: * Non-melanoma skin cancer, in situ cervical cancer, or breast cancer in situ * Prior malignancy completely excised or removed and patient has been continuously disease free for \> 5 years * Patients with completely excised or removed breast cancer and disease free \> 5 years, regardless of the continuation of hormonal therapy * Patients with previous radiation therapy (RT) to the pelvic region will be ineligible * Patients must be ≥ 18 years old * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * STEP 2: RANDOMIZATION (HIGH RISK PATIENTS - ARMS A AND B ONLY) * Within 2 weeks prior to randomization, postoperative absolute granulocyte count (AGC) must be \>= 1500/mm\^3 (or \< 1500/mm\^3, if in the opinion of the investigator, this represents an ethnic or racial variation of normal) * Within 2 weeks prior to randomization, the postoperative platelet count must be \>= 100,000/mm\^3 * Within 2 weeks prior to randomization, there must be postoperative evidence of adequate hepatic function; bilirubin must be =\< upper limit of normal (ULN) unless the patient has a chronic grade 1 bilirubin elevation due to Gilbert's disease or similar syndrome due to slow conjugation of bilirubin * Within 2 weeks prior to randomization, there must be postoperative evidence of adequate hepatic function; alkaline phosphatase must be \< 2.5 x ULN * Within 2 weeks prior to randomization, there must be postoperative evidence of adequate hepatic function; aspartate transaminase (AST) must be \< 1.5 x ULN * Within 2 weeks prior to randomization, there must be postoperative evidence of adequate renal function; serum creatinine =\< 1.5 x ULN * Within 2 weeks prior to randomization, there must be postoperative evidence of adequate renal function; urine protein/creatinine (UPC) ratio of \< 1.0; patients with a UPC ratio \>= 1.0 must undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \< 1 gm of protein in order to participate * Patients with any significant bleeding that is not related to the primary colon tumor within 6 months prior to study entry are not eligible * Patients with gastroduodenal ulcer(s) determined to be active by endoscopy are not eligible * Patients with a history of hypertension must measure \< 150/90 mmHg and be on a stable regimen of anti-hypertensive therapy * Patients must not have a serious or non-healing wound, skin ulcers or bone fracture * Patients experiencing clinically significant peripheral neuropathy at the time of step 2 randomization (defined in the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events version 4.0 \[CTCAE 4.0\] as grade 2 or greater neurosensory or neuromotor toxicity) are not eligible * Patients must not have had invasive procedures, defined as follows: * Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization * Core biopsy or other minor procedure, excluding placement of a vascular access device, within 7 days prior to randomization * Or anticipate the need for major surgical procedure(s) during the course of the study * Patients must begin adjuvant treatment no less than 28 days and no more than 60 days from surgery * Eligible patients of reproductive potential (both sexes) must agree to use an accepted and effective method of contraceptive during study therapy and for at least 3 months after the completion of bevacizumab; women must not be pregnant or breast-feeding because the study drugs administered may cause harm to an unborn fetus or breastfeeding child; all females of childbearing potential must have a serum pregnancy test to rule out pregnancy within 2 weeks prior to step 2 randomization * Patients with prothrombin time (PT) (international normalized ratio \[INR\]) \> 1.5 are not eligible, unless the patient is on full-dose anticoagulants; if so, the following criteria must be met for enrollment: * The subject must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on a stable dose of low molecular weight heparin * The subject must not have active bleeding or a pathological condition that is associated with a high risk of bleeding * Patients with non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study therapy drugs are not eligible; specifically excluded are the following conditions: * New York Heart Association (NYHA) class III or IV congestive heart failure * Current symptomatic arrhythmia * Any non-malignant systemic disease * Patients with a history of transient ischemic attack (TIA) or cerebrovascular accident (CVA) are not eligible * Patients with a history of the following within twelve months of study entry are not eligible: * Arterial thromboembolic events * Unstable angina * Myocardial infarction * Patients with symptomatic peripheral vascular disease are not eligible * Patients with psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude them from meeting the study requirements are not eligible * Patients must not have a known allergy to platinum compounds * STEP 2: REGISTRATION (LOW-RISK PATIENTS - ARM C) * Patients determined to be low risk are eligible
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive oxaliplatin IV over 2 hours and leucovorin IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Fluorouracil
    2. Drug: Leucovorin
    3. Drug: Oxaliplatin
    label
    Arm A (5-FU, leucovorin, oxaliplatin)
    type
    ACTIVE_COMPARATOR
  2. description
    Patients receive oxaliplatin, leucovorin, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: Bevacizumab
    2. Drug: Fluorouracil
    3. Drug: Leucovorin
    4. Drug: Oxaliplatin
    label
    Arm B (5-FU, leucovorin, oxaliplatin, bevacizumab)
    type
    EXPERIMENTAL
  3. description
    Patients undergo observation.
    label
    Arm C (observation)
    type
    NO_INTERVENTION
interventions
  1. arm Group Labels
    1. Arm B (5-FU, leucovorin, oxaliplatin, bevacizumab)
    description
    Given IV
    name
    Bevacizumab
    other Names
    1. ABP 215
    2. ABP-215
    3. ABP215
    4. Alymsys
    5. Anti-VEGF
    6. Anti-VEGF Humanized Monoclonal Antibody
    7. Anti-VEGF Monoclonal Antibody SIBP04
    8. Anti-VEGF rhuMAb
    9. Avastin
    10. Avegra
    11. Avzivi
    12. Aybintio
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Arm A (5-FU, leucovorin, oxaliplatin)
    2. Arm B (5-FU, leucovorin, oxaliplatin, bevacizumab)
    description
    Given IV
    name
    Fluorouracil
    other Names
    1. 5 Fluorouracil
    2. 5 Fluorouracilum
    3. 5 FU
    4. 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
    5. 5-Fluorouracil
    6. 5-Fluracil
    7. 5-Fu
    8. 5FU
    9. AccuSite
    10. Carac
    11. Fluoro Uracil
    12. Fluouracil
    type
    DRUG
  3. arm Group Labels
    1. Arm A (5-FU, leucovorin, oxaliplatin)
    2. Arm B (5-FU, leucovorin, oxaliplatin, bevacizumab)
    description
    Given IV
    name
    Leucovorin
    other Names
    1. Folinic acid
    type
    DRUG
  4. arm Group Labels
    1. Arm A (5-FU, leucovorin, oxaliplatin)
    2. Arm B (5-FU, leucovorin, oxaliplatin, bevacizumab)
    description
    Given IV
    name
    Oxaliplatin
    other Names
    1. 1-OHP
    2. Ai Heng
    3. Aiheng
    4. Dacotin
    5. Dacplat
    6. Diaminocyclohexane Oxalatoplatinum
    7. Eloxatin
    8. Eloxatine
    9. Elplat
    10. JM 83
    11. JM-83
    12. JM83
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
2431
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    The association between onset of neurotoxicity and oxaliplatin exposure will be assessed. The difference in neurotoxicity rates between patients with and without a given polymorphism will be evaluated.
    measure
    The Association Between Oxaliplatin Exposure, Allelic Variants in Candidate Genes, and Neurotoxicity
    time Frame
    Assessed at baseline, every 2 weeks while on treatment, up to 10 years
primary Outcomes
  1. description
    Disease-free survival (DFS) is defined as the time from randomization to the earlier of disease recurrence, new invasive primary cancer, or death from any cause. The Kaplan-Meier estimates were used to characterize the 5-year DFS rates.
    measure
    Disease-free Survival Rate at 5 Years
    time Frame
    Assessed every 3 months for patients within 2 years of step 2 randomization, every 6 months during 3-5 years from step 2 randomization, and then every 12 months until 10 years from step 2 randomization
secondary Outcomes
  1. description
    Overall survival (OS) is defined as the time from randomization to death from any cause. OS is censored at the date of last contact for patients still alive. The Kaplan-Meier estimates were used to characterize the 5-year OS rates.
    measure
    Overall Survival Rate at 5 Years
    time Frame
    Assessed every 3 months for patients within 2 years of step 2 randomization, every 6 months during 3-5 years from step 2 randomization, and then every 12 months until 10 years from step 2 randomization
  2. description
    Overall survival (OS) is defined as the time from randomization to death from any cause. OS is censored at the date of last contact for patients still alive. The following patient/tumor characteristics were associated with overall survival: * ECOG Performance Status (0, 1, or 2) * Age * Sex (male, female) * Primary tumor site (right-side colon, transverse colon, left-side colon, or other) * Number of regional lymph nodes Hazard ratios with adjustment for other covariates are reported with OS as the outcome variable.
    measure
    The Impact of Tumor Biological Characteristics on Overall Survival
    time Frame
    Assessed at baseline, every 3 months for patients within 2 years of step 2 randomization, every 6 months during 3-5 years from step 2 randomization, and then every 12 months until 10 years from step 2 randomization
Full study description
brief Summary
This randomized phase III trial studies oxaliplatin, leucovorin, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer.
detailed Description
PRIMARY OBJECTIVES: I. To demonstrate an improvement in 3-year disease-free survival for high-risk stage II colon cancer patients randomly assigned to 5-FU (fluorouracil), leucovorin, oxaliplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab. SECONDARY OBJECTIVES: I. To compare overall survival between the regimens. II. To further define the toxicity profiles of the regimens. III. To prospectively determine the impact of tumor biological characteristics on the survival of patients with stage II colon cancer. IV. To assess the association between oxaliplatin exposure, allelic variants in candidate genes, and neurotoxicity. (Pharmacogenetic ancillary objective) OUTLINE: Patients with high-risk disease are randomized to 1 of 2 treatment arms (Arms A and B). Patients with low-risk disease are assigned to Arm C. ARM A: Patients receive oxaliplatin intravenously (IV) over 2 hours and leucovorin IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive oxaliplatin, leucovorin, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity. ARM C: Patients undergo observation. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then every 12 months for 10 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-9f1ee863f0fe84fa056e
      requested nct id
      NCT00217737
      primary nct id
      NCT00217737
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
      payload sha256
      0041b4e7e27512078a89d72c4f282924d2b4c8a7abf1f66af500eec364c5c2c8
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-9f1ee863f0fe84fa056e
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00217737
      occurrences
      1. context exact
        d arm in the latest Intergroup study evaluating adjuvant chemotherapy in rectal cancer. An Eastern Cooperative Oncology Group trial (<a href="/clinicaltrials/NCT00217737">ECOG-E5202</a> [NCT00217737]) randomly assigned patients with stage II or III rectal cancer who received preoperative or postoperative chemoradiation therapy
        end
        212460
        exact text
        NCT00217737
        start
        212449
      2. context exact
        p study evaluating adjuvant chemotherapy in rectal cancer. An Eastern Cooperative Oncology Group trial (<a href="/clinicaltrials/NCT00217737">ECOG-E5202</a> [NCT00217737]) randomly assigned patients with stage II or III rectal cancer who received preoperative or postoperative chemoradiation therapy to receive 6 months of FOLFOX
        end
        212489
        exact text
        NCT00217737
        start
        212478
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/000ed4364d31964822.html
      source file sha256
      a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:38.943216+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      387f265965c4b56957c6f58b4d8eb54b8d5a660b7f6ef6c433eff171e69dbb77
      source title
      Rectal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025

    Preserved source evidence · Independent clinical review pending · Not medical advice